The expansion is said to increase the company’s capability to manufacture complex APIs and generate new jobs at the Rensselaer facility
Curia’s Rensselaer, New York facility. (Credit: Business Wire.)
Curia, previously called AMRI, has revealed its plans to expand the commercial manufacturing capacity at its pharmaceutical plant in Rensselaer County, New York.
The company has announced an investment of more than $35m in the expanded manufacturing and product-handling solutions for complex small molecules.
Its Rensselaer facility offers high-quality active pharmaceutical ingredients (APIs) to meet the development and commercial needs of more than 50 products.
As part of the expansion, Curia will upgrade the new vessel capacities that would more than double the facility’s batch-size scaling and product output.
The expansion is said to increase the company’s capability to manufacture complex APIs and generate new jobs at the Rensselaer facility.
Also, it will enable Curia to introduce a variety of new products and address the growing demand for high potency API manufacturing.
The expansion is expected to be completed within 18 months, adding to its existing API manufacturing facilities in the US, France, Spain, Italy and India.
Curia chairman and CEO John Ratliff said: “Our Rensselaer team’s history of excellence in delivering U.S.-based complex manufacturing solutions that enable our customers to provide vital treatments to patients is resulting in increasing demand.
“Some of the life-saving products produced at Rensselaer are highly complex, including critical oncology therapeutics and novel treatments addressing unmet medical needs.
“The engineering and technology advances we have designed for the site will enhance our flexibility, efficiency and scale, allowing us to meet our customers’ current and future complex manufacturing needs.”
Recently, Curia closed the acquisition of Integrity Bio, a privately held formulation and fill-finish organization headquartered in Camarillo, California.
The acquisition is said to enhance the company’s drug product formulation development capabilities and expands its fill-finish network.
Curia is a contract research, development and manufacturing organisation (CDMO), providing products and services to pharmaceutical and biopharmaceutical customers.
It has 3,400 employees, working at 23 locations across the US, Europe and Asia.